Johnson & Johnson JNJ

$275.58 +3.26 (1.20%)

Valuation

Market cap
665,187,904,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
24.99
P/E (forward)
23.94
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
3,628,428
Avg volume
7,182,336
Day's range
$265.55 – $275.61
Shares out
2,407,310,000
Stochastic %K
46%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

TraderDaKing Nov 6, 6:36 PM 0 replies
BigAllergies Nov 6, 5:08 PM
$JNJ's Quality Score reached 15 or more five times in the past year. A month later, shares were higher four times and lower one. getbreakaway.com/JNJ
0 replies
BurchJJ Nov 6, 4:30 PM
$CNSY YEP. TOLD YOU NOW MOVING ENJOY THE RUN UP FOLKS $JNJ $MRNA $QQQ
0 replies
STACKD0E Nov 6, 3:46 PM
$JNJ 👁
0 replies
BurchJJ Nov 6, 3:17 PM
$CNSY YES! MARKET MAKERS NOW MOVING IN TO ACCUMULATE VOLUME TRIGGERING EXPLOSIVE MOVE UP LIKELY $MRNA $JNJ $QQQ
1 replies
BurchJJ Nov 6, 2:58 PM
$CNSY bottom/revearsal CONFIRMED watching for a dramatic spike into the weekend $QQQ $CRWV $JNJ
1 replies
Rayvio_News_Filter Nov 6, 2:58 PM
$JNJ · $HALO 🏥 The U.S. FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), co-formulated with Halozyme's ENHANZE, as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Curated for market relevance
0 replies
AlertsAndNews Nov 6, 3:31 AM
$JNJ FDA approval Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer "Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent"
0 replies